Program
Denosumab
Also written as “denosumab”, “CT-P41” and “AMG 162”.
Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis · Breast Neoplasms · Giant Cell Tumor of Bone · Prostatic Neoplasms, led by 13 companies.
Drug pageDenosumab: every studyMany companies study it; this page follows only the 78 they lead. All 207 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgenits history only | 553 open or running | phase 4since Nov 20, 2012 | Aug 6, 2002 | Jan 23, 2027phase 4 · NCT06332014 |
| GlaxoSmithKlineits history only | 50 open or running | phase 3since Oct 20, 2011 | Oct 20, 2011 | none ahead |
| Celltrionits history only | 30 open or running | phase 3since Feb 12, 2021 | Aug 11, 2020 | none ahead |
| Mabwell (Shanghai) Bioscienceits history only | 30 open or running | phase 3since Jan 18, 2022 | Mar 12, 2021 | none ahead |
| Daiichi Sankyoits history only | 20 open or running | phase 3since May 16, 2008 | May 16, 2008 | none ahead |
| Fosun Pharmaits history only | 20 open or running | phase 3since Apr 23, 2022 | Aug 27, 2020 | none ahead |
| Shanghai Biomabs Pharmaceutical | 20 open or running | phase 3since Oct 15, 2020 | Apr 18, 2019 | none ahead |
| AryoGen Pharmedits history only | 10 open or running | phase 3since Sep 19, 2017 | Sep 19, 2017 | none ahead |
| Hamad Medicalits history only | 10 open or running | phase 3since Jan 22, 2017 | Jan 22, 2017 | none ahead |
| Lambda Therapeutic Researchits history only | 11 open or running | phase 3since Jun 7, 2022 | Jun 7, 2022 | none ahead |
| Luye Pharma Groupits history only | 11 open or running | phase 3since May 2, 2023 | May 2, 2023 | none ahead |
| Samsung Bioepisits history only | 10 open or running | phase 1since Nov 3, 2020 | Nov 3, 2020 | none ahead |
| Taizhou Mabtech Pharmaceuticalits history only | 10 open or running | phase 1since Apr 7, 2024 | Apr 7, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Shanghai Biomabs Pharmaceutical only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 18, 2019First study: phase 1 study in Osteoporosis, PostmenopausalFirst studyNCT03925051 · 132 enrolled · China
- Oct 15, 2020Phase 3 study in Osteoporosis, PostmenopausalNCT04591275 · 278 enrolled · China
TargetBeta
“A fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa beta ligand (RANKL) with antiosteoclast activity”NCIt, by rule
“Tumor necrosis factor ligand superfamily member 11 inhibitor”ChEMBL 37, by rule
Other programs on TNFSF11
Studies
All 2 Shanghai Biomabs Pharmaceutical leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04591275Osteoporosis, Postmenopausal · China | 3 | Completed | Nov 1, 2024 | 278 |
| NCT03925051Osteoporosis, Postmenopausal · China | 1 | Completed | Mar 21, 2020 | 132 |
How it is read
Names in the registry
- “Denosumab”, 41 entries
- “denosumab”, 10 entries
- “CT-P41”, 3 entries
- “AMG 162”, 3 entries
- “Prolia®”, 2 entries
Codes read as this program: CMAB807.
Conditions, from the studies’ own filings
- Osteoporosis, Postmenopausal, 21 studies
- Osteoporosis, 16 studies
- Breast Neoplasms, 5 studies
- Giant Cell Tumor of Bone, 4 studies
- Prostatic Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.